Entasis Therapeutics, Inc.

Thomas Francois Durand-Reville

Ruben Alberto Tommasi

Janelle Comita-Prevoir

Jeroen Cunera Verheijen

Satenig Guler

Neil Bifulco

Bolin Geng

Hoan Huynh

Xiaoyun Wu

Brendan Chen

Liang Zhao

Shanta Bist

Hui Xiong

Jing Zhang

Ye Wu

Daemian Dussault

Jan Romero

Boudewijn Lodewijk Maria DeJonge

John Mueller

Frank Wu

Helen Mcguire

Lise Gauthier

Helen McGuire

John O'Donnell

Mark Sylvester

Camilo Velez-Vega

Ruben Tommasi

Gregory S Basarab

Bill Moss

Boudewijn Lodewijk Maria Dejonge

Boudewijn Lodewijk Dejonge

Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R, R, and Rare as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I. 

Compounds and methods for treating bacterial infections

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, R, R, Rand Rare described herein. 

Beta-lactamase inhibitor compounds

The present invention is directed to combinations of a &#x3b2;-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of &#x3b2;-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof. 

Combination therapy for treatment of resistant bacterial infections

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

&#x3b2;-lactamase inhibitor compounds

Growing community of inventors

Belmont, MA, United States of America

Thomas Francois Durand-Reville